Ocular Therapeutix logo

Ocular Therapeutix Share Price Today

(NASDAQ: OCUL)

Ocular Therapeutix share price is $7.15 & ₹621.83 as on 6 Mar 2025, 2.30 'hrs' IST

$7.15

0.65

(10%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Ocular Therapeutix share price in Dollar and Rupees. Guide to invest in Ocular Therapeutix stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Ocular Therapeutix, along with analyst recommendations, forecasts, and comprehensive financials.

Ocular Therapeutix share price movements

  • Today's Low: $6.53
    Today's High: $7.21

    Day's Volatility :9.37%

  • 52 Weeks Low: $4.06
    52 Weeks High: $11.78

    52 Weeks Volatility :65.52%

Ocular Therapeutix (OCUL) Returns

PeriodOcular Therapeutix IncSector (Health Care)Index (Russel 2000)
3 Months
-22.11%
3.7%
0.0%
6 Months
-15.28%
-2.8%
0.0%
1 Year
-33.98%
2.5%
0.0%
3 Years
41.58%
12.9%
-11.6%

Ocular Therapeutix (OCUL) Key Statistics

in dollars & INR

Previous Close
$6.5
Open
$6.53
Today's High
$7.205
Today's Low
$6.53
Market Capitalization
$1.0B
Today's Volume
$2.6M
52 Week High
$11.775
52 Week Low
$4.06
Revenue TTM
$63.7M
EBITDA
$-168.0M
Earnings Per Share (EPS)
$-1.33
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-95.21%

How to invest in Ocular Therapeutix Stock (OCUL) from India?

It is very easy for Indian residents to invest directly in Ocular Therapeutix from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Ocular Therapeutix stock in both Indian Rupees (INR) and US Dollars (USD). Search for Ocular Therapeutix or OCUL on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Ocular Therapeutix or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Ocular Therapeutix shares which would translate to 0.122 fractional shares of Ocular Therapeutix as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Ocular Therapeutix, in just a few clicks!

Returns in Ocular Therapeutix (OCUL) for Indian investors in Rupees

The Ocular Therapeutix stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Ocular Therapeutix investment value today

Current value as on today

₹70,969

Returns

₹29,031

(-29.03%)

Returns from Ocular Therapeutix Stock

₹33,980 (-33.98%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Ocular Therapeutix (OCUL)

20%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Ocular Therapeutix Stock from India on INDmoney has increased by 20% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Ocular Therapeutix

  • SUMMER ROAD LLC

    8.82%

  • Deep Track Capital, LP

    8.16%

  • VR Adviser, LLC

    8.12%

  • BlackRock Inc

    7.54%

  • Vanguard Group Inc

    5.40%

  • venBio Select Advisor LLC

    5.13%

Analyst Recommendation on Ocular Therapeutix

Buy

    85%Buy

    14%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Ocular Therapeutix(by analysts ranked 0 to 5 stars)

Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
2
2
2
Sell
0
0
0

Analyst Forecast on Ocular Therapeutix Stock (OCUL)

What analysts predicted

Upside of 148.64%

Target:

$17.78

Current:

$7.15

Insights on Ocular Therapeutix Stock (Ticker Symbol: OCUL)

  • Price Movement

    In the last 7 days, OCUL stock has moved up by 3.0%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 15.42M → 17.08M (in $), with an average increase of 9.7% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -36.49M → -48.38M (in $), with an average decrease of 32.6% per quarter
  • OCUL vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 100.5%
  • OCUL vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 6.6%
  • Price to Sales

    ForOCUL every $1 of sales, investors are willing to pay $17.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Ocular Therapeutix Technicals Summary

Sell

Neutral

Buy

Ocular Therapeutix is currently in a neutral trading position according to technical analysis indicators.

Ocular Therapeutix (OCUL) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ocular Therapeutix Inc logo
-8.57%
-15.28%
-33.98%
41.58%
17.6%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ocular Therapeutix Inc logo
NA
NA
0.0
-1.22
-0.95
-0.3
NA
2.0
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ocular Therapeutix Inc logo
Buy
$1.0B
17.6%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Ocular Therapeutix

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Organization
Ocular Therapeutix
Employees
274
CEO
Dr. Pravin U. Dugel M.D.
Industry
Health Technology

Management People of Ocular Therapeutix

NameTitle
Mr. Donald Notman Jr.
CFO, COO & Principal Accounting Officer
Dr. Jeffrey S. Heier M.D.
Chief Scientific Officer
Dr. Pravin U. Dugel M.D.
Executive Chairman, President & CEO
Dr. Peter K. Jarrett Ph.D.
Chief Technology Officer
Mr. William S. Slattery Jr.
Vice President of Investor Relations
Mr. Todd D.C. Anderman J.D.
Chief Legal Officer & Corporate Secretary
Mr. William H. Ransone II
Vice President of Global Sales & Marketing
Mr. Barry Rubenstein M.S.
Chief Human Resources Officer
Mr. Steve Meyers
Chief Commercial Officer
Dr. Peter K. Kaiser M.D.
Chief Development Officer

Important FAQs about investing in OCUL Stock from India :

What is Ocular Therapeutix share price today?

Ocular Therapeutix share price today stands at $7.15, Open: $6.53 ; Previous Close: $6.50 ; High: $7.21 ; Low: $6.53 ; 52 Week High: $11.78 ; 52 Week Low: $4.06.

The stock opens at $6.53, after a previous close of $6.50. The stock reached a daily high of $7.21 and a low of $6.53, with a 52-week high of $11.78 and a 52-week low of $4.06.

Can Indians buy Ocular Therapeutix shares?

Yes, Indians can invest in the Ocular Therapeutix (OCUL) from India.

With INDmoney, you can buy Ocular Therapeutix at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Ocular Therapeutix at zero transaction cost.

How can I buy Ocular Therapeutix shares from India?

It is very easy to buy Ocular Therapeutix from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Ocular Therapeutix (OCUL) be purchased?

Yes, you can buy fractional shares of Ocular Therapeutix with INDmoney app.

What are the documents required to start investing in Ocular Therapeutix stocks?

To start investing in Ocular Therapeutix, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Ocular Therapeutix Stock (OCUL)?

Today’s highest price of Ocular Therapeutix (OCUL) is $7.21.

Today’s lowest price of Ocular Therapeutix (OCUL) is $6.53.

What is today's market capitalisation of Ocular Therapeutix?

Today's market capitalisation of Ocular Therapeutix OCUL is 1.0B

What is the 52 Week High and Low Range of Ocular Therapeutix Stock (OCUL)?

  • 52 Week High

    $11.78

  • 52 Week Low

    $4.06

What are the historical returns of Ocular Therapeutix (OCUL)?

  • 1 Month Returns

    -8.57%

  • 3 Months Returns

    -15.28%

  • 1 Year Returns

    -33.98%

  • 5 Years Returns

    17.6%

Who is the Chief Executive Officer (CEO) of Ocular Therapeutix ?

Dr. Pravin U. Dugel M.D. is the current Chief Executive Officer (CEO) of Ocular Therapeutix.